Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.

UNLABELLED The biologic mechanisms involved in the intratumoral heterogeneous distribution of 18F-FDG have not been fully investigated. To clarify factors inducing heterogeneous 18F-FDG distribution, we determined the intratumoral distribution of 18F-FDG by autoradiography (ARG) and compared it with the regional expression levels of glucose transporters Glut-1 and Glut-3 and hexokinase-II (HK-II) in a rat model of malignant tumor. METHODS Rats were inoculated with allogenic hepatoma cells (KDH-8) into the left calf muscle (n = 7). Tumor tissues were excised 1 h after the intravenous injection of 18F-FDG and sectioned to obtain 2 adjacent slices for ARG and histochemical studies. The regions of interest (ROIs) were placed on ARG images to cover mainly the central (CT) and peripheral (PT) regions of viable tumor tissues and necrotic/apoptotic (NA) regions. The radioactivity in each ROI was analyzed quantitatively using a computerized imaging analysis system. The expression levels of Glut-1, Glut-3, and HK-II were determined by immunostaining and semiquantitative evaluation. The hypoxia-inducible factor 1 (HIF-1) was also immunostained. RESULTS ARG images showed that intratumoral 18F-FDG distribution was heterogeneous. The accumulation of 18F-FDG in the CT region was the highest, which was 1.6 and 2.3 times higher than those in the PT and NA regions, respectively (P < 0.001). The expression levels of Glut-1, Glut-3, and HK-II were markedly higher in the CT region (P < 0.001) compared with those in the PT region. The intratumoral distribution of 18F-FDG significantly correlated with the expression levels of Glut-1, Glut-3, and HK-II (r = 0.923, P < 0.001 for Glut-1; r = 0.829, P < 0.001 for Glut-3; and r = 0.764, P < 0.01 for HK-II). The positive staining of HIF-1 was observed in the CT region. CONCLUSION These results demonstrate that intratumoral 18F-FDG distribution corresponds well to the expression levels of Glut-1, Glut-3, and HK-II. The elevated expression levels of Glut-1, Glut-3, and HK-II, induced by hypoxia (HIF-1), may be contributing factors to the higher 18F-FDG accumulation in the CT region.

[1]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[2]  G. Glatting,et al.  Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Y. Nishimura,et al.  Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  N. Tamaki,et al.  Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions , 2001, European Journal of Nuclear Medicine.

[5]  R L Wahl,et al.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  R L Wahl,et al.  An Immunohistochemical Study , 2006 .

[8]  M. Birnbaum,et al.  Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. , 1987, Science.

[9]  T. Ido,et al.  Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  W. Chapman,et al.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  N. Tamaki,et al.  Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading , 2002, Nuclear medicine communications.

[12]  Cyrill Burger,et al.  The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  R L Wahl,et al.  Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  R Iwata,et al.  Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[16]  N. Tamaki,et al.  FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Yagata,et al.  Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.

[18]  G. van Kaick,et al.  FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. , 1994, Nuclear medicine and biology.

[19]  W C Eckelman,et al.  Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. , 1999, Cancer research.

[20]  T. A. Smith,et al.  Mammalian hexokinases and their abnormal expression in cancer. , 2000, British journal of biomedical science.

[21]  G. Semenza,et al.  Levels of Hypoxia-Inducible Factor-1α During Breast Carcinogenesis , 2001 .

[22]  Mark A. Stephenson,et al.  Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.

[23]  R. Wahl,et al.  Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  N. Tamaki,et al.  Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  T. Ido,et al.  Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  S. Bessman,et al.  Hexokinase Binding to Mitochondria: A Basis for Proliferative Energy Metabolism , 1997, Journal of bioenergetics and biomembranes.

[27]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[28]  G. Lucignani,et al.  The role of molecular imaging in precision radiation therapy for target definition, treatment planning optimisation and quality control , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Julie Sutcliffe-Goulden,et al.  Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  T. Suzuki,et al.  Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. , 1999, European journal of biochemistry.

[31]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Jewett,et al.  Routine production of 2-deoxy-2-[18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[33]  Jeih-San Liow,et al.  Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  G I Bell,et al.  Structure and function of mammalian facilitative sugar transporters. , 1993, The Journal of biological chemistry.

[35]  R. Iwata,et al.  Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  H. Lodish,et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.

[37]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  I. Whittle,et al.  The development of necrosis and apoptosis in glioma: experimental findings using spheroid culture systems* , 2001, Neuropathology and applied neurobiology.

[39]  R L Wahl,et al.  Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.